38.22
+0.7(+1.87%)
Currency In USD
| Previous Close | 37.52 |
| Open | 38.03 |
| Day High | 38.24 |
| Day Low | 36.85 |
| 52-Week High | 63.5 |
| 52-Week Low | 26.2 |
| Volume | 649,024 |
| Average Volume | 773,580 |
| Market Cap | 2.24B |
| PE | -9.23 |
| EPS | -4.14 |
| Moving Average 50 Days | 37.71 |
| Moving Average 200 Days | 38.95 |
| Change | 0.7 |
If you invested $1000 in Apogee Therapeutics, Inc. (APGE) since IPO date, it would be worth $1,800.28 as of September 29, 2025 at a share price of $38.22. Whereas If you bought $1000 worth of Apogee Therapeutics, Inc. (APGE) shares 1 year ago, it would be worth $650.66 as of September 29, 2025 at a share price of $38.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
GlobeNewswire Inc.
Sep 11, 2025 11:30 AM GMT
SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammator
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
GlobeNewswire Inc.
Sep 03, 2025 11:30 AM GMT
SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on T
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
GlobeNewswire Inc.
Jul 07, 2025 10:00 AM GMT
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week 16, the highest topline and placebo